Liquidia Corporation

Inhaled/dry-powder cardiopulmonary therapeutics (PRINT technology)

LQDA · Nasdaq · United States

Share price · LQDA

$56.40-17.93 (-24.12%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.3M (0.3x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when LQDA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 14 Oct 2026+26.6%
  2. 30 Sep 2026-57.2%
  3. 28 Sep 2026+7.7%

    Nothing announced by LQDA that day or the session before.

  4. 13 Aug 2026-8.5%
  5. 12 Aug 2026-10.5%
  6. 4 Jun 2026+12.3%

    Nothing announced by LQDA that day or the session before.

  7. 11 May 2026+25.6%
  8. 25 Feb 2026-10.6%

    Nothing announced by LQDA that day or the session before.

  9. 17 Feb 2026-11.4%

    Nothing announced by LQDA that day or the session before.

  10. 9 Jan 2026+12.9%

Share of unusual movement by asset

For each asset, the share of LQDA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Treprostinil (Yutrepia, Liquidia) (Yutrepia)
events and moves
911%
Other company news (earnings, financing, releases naming no asset)—45%
Sessions with no dated event—45%

Assets

(2 total)
2Total Assets
1Approved
1Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Approved
IP receptor (prostacyclin pathway)Small molecule
Pulmonary Arterial HypertensionPulmonary Hypertension Associated with Interstitial Lung DiseaseSystemic Sclerosis
Phase 3
IP receptor (prostacyclin pathway)Small molecule
Pulmonary Arterial HypertensionPulmonary Hypertension Associated with Interstitial Lung Disease

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
February 2027 (1)
Treprostinil (Yutrepia, Liquidia)Phase 2Raynaud's Phenomenon Secondary to Systemic Sclerosis
Est. primary completion 2027-02 · NCT07748000 · CT.gov ↗
What to watch
2029 (1)
July 2029 (1)
Treprostinil (L606)Phase 3Pulmonary Hypertension Due to Lung Disease (Disorder)
Est. primary completion 2029-07 · NCT07285655 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (18)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$225M$25M$396M$236M$147M operating cash flowreport ↗
View 17 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$172M$17M$284M—$80M operating cash flowreport ↗
2026-Q1$133M$13M$223M—$53M operating cash flowreport ↗
2025-Q3$54M$9.3M$158M$3.5M-$9.8M operating cash flowreport ↗
2025-Q2$8.8M$6.0M$173M$42M-$39M operating cash flowreport ↗
2025-Q1$3.1M$7.0M$170M$38M-$31M operating cash flowreport ↗
2024-Q4$2.9M—$176M$39M-$21M operating cash flowreport ↗
2024-Q3$4.5M$12M$204M$23M-$25M operating cash flowreport ↗
2024-Q2$3.7M$9.4M$133M$28M-$23M operating cash flowreport ↗
2024-Q1$3.0M$10M$158M$41M-$25M operating cash flowreport ↗
2023-Q4$4.5M—$84M$27M-$16M operating cash flowreport ↗
2023-Q3$3.7M$7.4M$76M$16M-$12M operating cash flowreport ↗
2023-Q2$4.8M$18M$88M$24M-$5.6M operating cash flowreport ↗
2023-Q1$4.5M$5.3M$94M$12M-$8.5M operating cash flowreport ↗
2022-Q3$3.2M$4.5M$98M$9.1M-$5.8M operating cash flowreport ↗
2022-Q2$3.9M$5.2M$104M$9.4M-$8.4M operating cash flowreport ↗
2022-Q1$3.5M$4.7M$58M$16M-$9.8M operating cash flowreport ↗
2021-Q3$3.2M$4.5M$64M$7.3M-$5.8M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$158M$39M$191M$17M-$36M operating cash flowreport ↗

For full-year 2025, Liquidia reported total revenue of $158.32M, up 1030.9% YoY, driven by YUTREPIA net product sales of $148.3M and service revenue of $10.0M. R&D expenses were $39.28M, down 17.9% YoY, and cash and cash equivalents stood at $190.68M at year-end. The company reported a full-year net loss of $68.92M, while fourth-quarter 2025 net income was $14.6M with positive non-GAAP adjusted EBITDA of $27.3M.

Following YUTREPIA’s FDA approval in May 2025 and US launch in June 2025, the company had received more than 3,600 unique prescriptions and started over 2,900 patients on treatment, with approximately 860 prescribers. Management said it plans to deepen prescriber adoption, grow the sales force, expand YUTREPIA’s clinical evidence through additional studies, and advance L606 into pivotal trials, all intended to be funded from operations. L606 is being evaluated in an open-label US study for PAH and PH-ILD and in a global pivotal placebo-controlled study for PH-ILD; the company also noted ongoing YUTREPIA-related litigation that could affect continued commercialization.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$14M$48M$176M$33M-$93M operating cash flowreport ↗
2023-FY$17M$43M$84M$20M-$42M operating cash flowreport ↗
2022-FY$16M$19M$93M$10M-$29M operating cash flowreport ↗
2021-FY$13M$21M$57M$8.7M-$34M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($318K), 170 sales ($227.0M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-16Alterson Harold · See RemarksAward / grant5,322——Form 4
2026-11-16KIRSCH ARTHUR S · directorOption exercise8,914$20.36$181KForm 4
2026-11-16Schundler Russell · See RemarksAward / grant8,870——Form 4
2026-11-16KIRSCH ARTHUR S · directorOption exercise (derivative)8,914——Form 4
2026-10-26Adair Jason · Chief Business OfficerOpen-market sale688$43.19$30KForm 4
2026-10-26Boyle Dana · Chief Accounting OfficerOpen-market sale1,581$43.19$68KForm 4
2026-10-12Khindri Sanjeev · Chief Development OfficerOpen-market sale1,101$28.48$31KForm 4
2026-10-12Boyle Dana · Chief Accounting OfficerOpen-market sale5,892$28.48$168KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 242 reporting institutions held 61.6M shares ($2.3B, 68.3% of shares outstanding).

#InstitutionSharesValue
1FARALLON CAPITAL MANAGEMENT LLC8,656,038$326.7M
2Caligan Partners LP8,118,892$306.4M
3BlackRock, Inc.5,489,144$207.2M
4FINDELL CAPITAL MANAGEMENT LLC3,502,112$132.2M
5VANGUARD CAPITAL MANAGEMENT LLC2,926,945$110.5M
6Opaleye Management Inc.2,545,000$88.8M
7BANK OF AMERICA CORP /DE/2,287,792$86.3M
8GEODE CAPITAL MANAGEMENT, LLC1,928,969$72.8M
9STATE STREET CORP1,881,599$71.0M
10MPM BIOIMPACT LLC1,405,158$53.0M
11Caprock Group, LLC1,367,235$51.6M
12SUSQUEHANNA INTERNATIONAL GROUP, LLP1,001,081$37.8M
13D. E. Shaw & Co., Inc.873,065$32.9M
14GOLDMAN SACHS GROUP INC811,990$30.6M
15JANE STREET GROUP, LLC795,884$30.0M